Benefits of investment into modern medicines in Central-Eastern European countries

András Inotai, Guenka Petrova, Dinko Vitezic, Z. Kaló

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Transferability of current evidence and expressing value of innovative pharmaceuticals according to health system objectives Due to the scarcity of healthcare resources, decision-makers often expect monetary benefits-including cost savings or productivity gain-from innovative medicines. Manufacturers try to fulfill this expectation by expressing the benefits of innovative technologies in monetary units citing approaches from the scientific literature. Unfortunately, currently available evidence has limited relevance and transferability in Central-Eastern European (CEE) countries. This study aims to summarize how innovative pharmaceuticals in CEE countries may contribute to WHO-defined health system objectives, including health gain, equity in health, financial protection, responsiveness, equity in finance and financial sustainability. References in this study are also mainly based on international examples; therefore, additional policy research from CEE countries is necessary to validate assumptions. If CEE politicians can rely on credible arguments based on local research evidence, they may improve long-term strategies and policy decisions related to healthcare innovation.

Original languageEnglish
Pages (from-to)71-79
Number of pages9
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume14
Issue number1
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Modern 1601-history
Health
Delivery of Health Care
Literature
Cost Savings
Research
Pharmaceutical Preparations
Cost-Benefit Analysis
Technology

Keywords

  • Equity
  • Financial protection
  • Health gain
  • Innovative medicines
  • Middle-income countries
  • Monetary benefit
  • Productivity
  • Responsiveness
  • Sustainability
  • Value of innovation

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy

Cite this

Benefits of investment into modern medicines in Central-Eastern European countries. / Inotai, András; Petrova, Guenka; Vitezic, Dinko; Kaló, Z.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 14, No. 1, 02.2014, p. 71-79.

Research output: Contribution to journalArticle

@article{91d5b9271d47466fbbb904d672b73499,
title = "Benefits of investment into modern medicines in Central-Eastern European countries",
abstract = "Transferability of current evidence and expressing value of innovative pharmaceuticals according to health system objectives Due to the scarcity of healthcare resources, decision-makers often expect monetary benefits-including cost savings or productivity gain-from innovative medicines. Manufacturers try to fulfill this expectation by expressing the benefits of innovative technologies in monetary units citing approaches from the scientific literature. Unfortunately, currently available evidence has limited relevance and transferability in Central-Eastern European (CEE) countries. This study aims to summarize how innovative pharmaceuticals in CEE countries may contribute to WHO-defined health system objectives, including health gain, equity in health, financial protection, responsiveness, equity in finance and financial sustainability. References in this study are also mainly based on international examples; therefore, additional policy research from CEE countries is necessary to validate assumptions. If CEE politicians can rely on credible arguments based on local research evidence, they may improve long-term strategies and policy decisions related to healthcare innovation.",
keywords = "Equity, Financial protection, Health gain, Innovative medicines, Middle-income countries, Monetary benefit, Productivity, Responsiveness, Sustainability, Value of innovation",
author = "Andr{\'a}s Inotai and Guenka Petrova and Dinko Vitezic and Z. Kal{\'o}",
year = "2014",
month = "2",
doi = "10.1586/14737167.2014.868314",
language = "English",
volume = "14",
pages = "71--79",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Benefits of investment into modern medicines in Central-Eastern European countries

AU - Inotai, András

AU - Petrova, Guenka

AU - Vitezic, Dinko

AU - Kaló, Z.

PY - 2014/2

Y1 - 2014/2

N2 - Transferability of current evidence and expressing value of innovative pharmaceuticals according to health system objectives Due to the scarcity of healthcare resources, decision-makers often expect monetary benefits-including cost savings or productivity gain-from innovative medicines. Manufacturers try to fulfill this expectation by expressing the benefits of innovative technologies in monetary units citing approaches from the scientific literature. Unfortunately, currently available evidence has limited relevance and transferability in Central-Eastern European (CEE) countries. This study aims to summarize how innovative pharmaceuticals in CEE countries may contribute to WHO-defined health system objectives, including health gain, equity in health, financial protection, responsiveness, equity in finance and financial sustainability. References in this study are also mainly based on international examples; therefore, additional policy research from CEE countries is necessary to validate assumptions. If CEE politicians can rely on credible arguments based on local research evidence, they may improve long-term strategies and policy decisions related to healthcare innovation.

AB - Transferability of current evidence and expressing value of innovative pharmaceuticals according to health system objectives Due to the scarcity of healthcare resources, decision-makers often expect monetary benefits-including cost savings or productivity gain-from innovative medicines. Manufacturers try to fulfill this expectation by expressing the benefits of innovative technologies in monetary units citing approaches from the scientific literature. Unfortunately, currently available evidence has limited relevance and transferability in Central-Eastern European (CEE) countries. This study aims to summarize how innovative pharmaceuticals in CEE countries may contribute to WHO-defined health system objectives, including health gain, equity in health, financial protection, responsiveness, equity in finance and financial sustainability. References in this study are also mainly based on international examples; therefore, additional policy research from CEE countries is necessary to validate assumptions. If CEE politicians can rely on credible arguments based on local research evidence, they may improve long-term strategies and policy decisions related to healthcare innovation.

KW - Equity

KW - Financial protection

KW - Health gain

KW - Innovative medicines

KW - Middle-income countries

KW - Monetary benefit

KW - Productivity

KW - Responsiveness

KW - Sustainability

KW - Value of innovation

UR - http://www.scopus.com/inward/record.url?scp=84893091107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893091107&partnerID=8YFLogxK

U2 - 10.1586/14737167.2014.868314

DO - 10.1586/14737167.2014.868314

M3 - Article

VL - 14

SP - 71

EP - 79

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 1

ER -